Booth #3302
Flatiron is excited to attend and present our research at the 2024 World Conference on Lung Cancer (WCLC), showcasing how our evidence solutions can be leveraged to bolster lung cancer research across the product development lifecycle.
At Flatiron, we’re constantly pushing the realm of possibilities with evidence solutions that support oncology portfolios across the development lifecycle.
At WCLC, we’re excited to showcase new innovative solutions to bolster lung cancer research, including:
Panoramic data with maximum cohort sizes spanning disease settings from our network of over 290K lung cancer patients
>7K NSCLC patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
Local real-world data (RWD) cohorts in the U.S., UK, Germany and Japan
Our research demonstrates the viability of real-world data and evidence to answer critical questions for patients with lung cancer, providing learnings to improve patient care and reduce inefficiencies in research.
Sunday, September 8
10:10–10:40 PST
Lung cancer research has entered an exciting new phase with over 30 novel therapy approvals over the past two decades. Much of this innovation centers on our evolving understanding of biomarkers as both predictive and prognostic, which has led to many important innovations across clinical research, drug commercialization and patient care. Real-world evidence unlocks insights critical to the research that helps us better understand biomarker-defined cohorts across disease settings and geographies. Join Emily Castellanos, MD, MPH, Senior Medical Director at Flatiron Health for her discussion on how Flatiron partners across the oncology ecosystem to turn data into practice-changing evidence.
Emily Castellanos, MD, MPH
Senior Medical Director, Flatiron Health
Flatiron’s local data in Germany, UK, and Japan fill a critical gap in global real-world evidence generation with the clinical depth and recency required to conduct rigorous lung cancer studies.
The CMDB offers Caris Life Sciences’ comprehensive whole-exome sequencing, whole-transcriptome sequencing and digital pathology data linked with Flatiron clinical data on over 56k+ linked patients.
Flatiron’s Panoramic Solutions, our largest real-world data cohorts, can be leveraged to maximize use cases across your lung cancer portfolio.
Read more about how 3 life sciences companies leveraged Flatiron’s network of over 290K lung cancer patients to support crucial research at various stages of the drug development lifecycle.
Read moreRead more about our accepted research at this year’s conference.
Author affiliations: Flatiron Health
Using machine learning, this study looked at how well chemoimmunotherapy (CIO), an established treatment option for resectable early non-small cell lung cancer, worked in the real-world setting. This research showed despite differences in outcomes based on cancer type and stage, overall, CIO usage was associated with improving the chances of staying free of distant metastasis.
Date: Monday, September 9
Time: 6:30 PM - 8 PM
Poster Session: P4.07F
Poster Code: 2446
Karen Schwed, FNP-BC
Clinical Director
Connect on LinkedIn
Author affiliations: Flatiron Health
Previous research has shown immune related adverse events have been linked to improved outcomes for patients with advanced non-small cell lung cancer (advNSCLC) who have received immunotherapy. This study assessed associations between real-world adverse events (rwAEs) and survival by race/ethnicity in a large immunotherapy treated advNSCLC cohort.
Date: Sunday, September 9
Time: 6 PM - 7:30 PM
Poster Session: P2.11A
Poster Code: 1780
Gene Ho, MPH
Research Scientist
Connect on LinkedIn
Author affiliations: Flatiron Health
Emerging targeted therapies have broadened treatment options for patients with advanced non–small cell lung cancer (advNSCLC), however, overall survival (OS), the gold standard in efficacy studies, requires an extended follow-up period and may be immature when other data options are available. This research suggests that rwPFS can potentially be a predictor of rwOS, reducing timelines to study efficacy in emerging treatments for advanced lung and other cancers.
E-Poster Session: EP.12G
Poster Code: 01
Xinran Ma
Senior Research Scientist
Connect on LinkedIn
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in lung cancer research, including:
Panoramic data with maximum cohort sizes spanning disease settings from our network of over 290K lung cancer patients
>7K NSCLC patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
Local real-world data (RWD) cohorts in the U.S., UK, Germany and Japan
Contact us to learn more about Flatiron’s tailored oncology evidence solutions.
